What Medicare’s New $50 GLP-1 Program Covers, and Where Coverage Is Shrinking

The landscape for insurance coverage of weight-loss medications like Wegovy and Zepbound is fragmenting across Medicare, Medicaid and commercial plans in 2026. Some coverage is expanding—Medicare added its first-ever temporary program in July—while other sources are shrinking or disappearing entirely.

What determines access now depends on which insurance system someone uses, where they live, and whether they meet increasingly specific medical criteria. A beneficiary who qualifies under one program may not qualify under another, or may face new restrictions or costs if their state or employer changes coverage rules.

Why Medicare is covering these drugs for the first time

Medicare prohibited Part D plans from covering anti-obesity medications for more than two decades, a restriction dating to the Medicare Prescription Drug, Improvement and Modernization Act of 2003. The original exclusion reflected medical skepticism from that era: weight-loss medications had faced safety concerns after the fen-phen scandal of the late 1990s, when the appetite suppressant combination fenfluramine and phentermine was linked to cardiovascular disease. There was broader skepticism too about whether obesity was a behavioral problem or a legitimate medical condition deserving pharmaceutical treatment.

The Medicare GLP-1 Bridge program, which launched July 1, 2026, represents the first opening in that decades-long ban. It is temporary by design, running through December 31, 2027—roughly 18 months of access while Medicare and the federal government evaluate longer-term coverage options. The program operates outside the standard Part D prescription drug benefit. Instead, Medicare pays participating pharmacies directly through a central processor, and beneficiaries pay a flat $50 copay per month for a one-month supply of any of the three covered drugs.

The three Medicare GLP-1 drugs covered in the bridge program
Wegovy (semaglutide injection or oral tablet), Zepbound (tirzepatide KwikPen), and Foundayo (orforglipron oral tablet, newly approved by Eli Lilly). All three carry a $50 monthly copay under the Medicare GLP-1 Bridge running from July 1, 2026, through December 31, 2027. The copay covers a one-month supply and does not count toward the Part D deductible or yearly out-of-pocket maximum.

Medicare’s new program: eligibility and what it covers

Three medications are covered under the bridge: Wegovy (available as both injections and oral tablets), Zepbound KwikPen, and Foundayo, a new GLP-1 pill made by Eli Lilly. The flat $50 monthly copay applies to all three, regardless of each drug’s actual cost. Participating manufacturers provide these medications at a reduced net price of approximately $245 per month, meaning the copay structure represents significant savings for those who qualify.

Eligibility is based on a combination of body mass index and other health conditions. Medicare covers the drugs for beneficiaries with a BMI of 35 or higher. Those with a BMI of 30 to 34 can qualify if they also have heart failure, uncontrolled high blood pressure, or chronic kidney disease. A lower BMI of 27 to 29 qualifies if the beneficiary has had a stroke, heart attack, symptomatic peripheral artery disease, or prediabetes. The criteria recognize obesity as interconnected with cardiovascular and metabolic disease, not as a standalone condition.

A critical feature is that the $50 copay does not count toward the beneficiary’s Part D deductible or yearly out-of-pocket maximum. That means the medication’s cost is separate from other prescription drug expenses, neither accelerating someone toward their deductible nor counting toward their out-of-pocket threshold. Access requires enrollment in a standalone prescription drug plan or a Medicare Advantage plan with drug coverage; Medicare pays pharmacies directly rather than through the individual Part D plan.

Medicaid’s fragmenting coverage landscape

Medicaid coverage for weight-loss drugs has become highly inconsistent. As of August 2026, only 20 of 51 states cover Wegovy or Zepbound for obesity treatment. By contrast, GLP-1 coverage for type 2 diabetes is far more consistent across state Medicaid programs, while coverage for cardiovascular risk reduction, obstructive sleep apnea, or weight loss varies by state.

The retrenchment accelerated in 2026. California, Michigan, and Pennsylvania all ended or restricted Medicaid coverage for GLP-1 drugs for weight loss in the first months of the year. Pennsylvania’s decision, effective January 1, 2026, was particularly stark: adults 21 and older lost coverage entirely, though minors retained it and adults could continue receiving GLP-1s if prescribed for other approved indications such as type 2 diabetes, obstructive sleep apnea with obesity, cardiovascular risk reduction, or metabolic dysfunction-associated steatohepatitis (MASH). The state required all current users to request new prior authorizations before December 31, 2025, to prevent coverage gaps.

Among states that retain coverage, all impose prior authorization requirements, meaning doctors must get approval from the Medicaid plan before the pharmacy dispenses the medication. Some states have tightened eligibility criteria. Michigan, for example, now covers the drugs for obesity only when used to avoid bariatric surgery in patients classified as morbidly obese—a narrow target rather than weight management for anyone meeting BMI thresholds. The fractured landscape means access depends entirely on where someone lives and whether their state kept coverage in place.

How commercial insurance determines who gets coverage

Private insurance coverage for weight-loss GLP-1s varies significantly by employer, and the rules for obtaining it have grown more layered in 2026. According to Mercer’s National Survey of Employer-Sponsored Health Plans, the most recent available data, nearly all employer health plans covered GLP-1s for diabetes in 2025, but only 49 percent of plans at companies with 500 or more employees covered them for weight loss, and two-thirds of companies with 20,000 or more workers did.

For plans that do cover GLP-1 medications for weight loss, the requirements are strict and multilayered. Most commercial insurers require a BMI of 30 or higher, or a BMI of 27 or higher if the patient has at least one weight-related comorbidity such as hypertension, type 2 diabetes, abnormal cholesterol, sleep apnea, or established cardiovascular disease. Before approval, providers must document evidence of attempted diet and lifestyle modifications over a defined period, and submit BMI calculations, relevant lab values, and supporting clinical notes. Prior authorization is nearly universal. A complete commercial prior authorization request typically takes five to ten business days to process when submitted electronically.

Many commercial plans also require periodic reauthorization, not treating initial approval as permanent. Coverage may be valid for only three, six, or twelve months, after which the provider must submit new documentation demonstrating continued clinical benefit and request approval again. Missing a reauthorization deadline can lead to sudden coverage gaps. Common denial reasons include incomplete documentation, missing evidence of prior treatment attempts, submitting under an incorrect diagnosis code, failing to try other weight-loss interventions first, or expired authorization.

Only 20 of 51 states cover Wegovy or Zepbound on Medicaid for weight loss, and three states ended or restricted coverage in early 2026, while Medicare’s bridge program offers a flat $50 monthly copay for its 18-month run through December 2027.

What happens after the Medicare bridge expires

The temporary nature of Medicare’s program introduces a significant uncertainty. Coverage ends December 31, 2027, leaving beneficiaries who have been using the bridge program with no clear replacement. The federal government has indicated that a longer-term “BALANCE Model” is under evaluation, potentially expanding Medicare coverage more broadly, but no final decision or timeline has been announced. Beneficiaries relying on the bridge program would face an access cliff at the end of 2027 unless Congress or CMS establishes permanent coverage before that date.

The fragmentation in 2026 reflects ongoing tension about whether obesity treatment is a medical necessity deserving insurance coverage or an elective lifestyle benefit. Medicare’s temporary bridge program signals that the federal government is treating it as medically necessary for seniors, at least temporarily. Medicaid’s retrenchment in multiple states suggests some governments are moving in the opposite direction, viewing obesity treatment as something individuals should manage with lifestyle changes and out-of-pocket medication costs. Commercial insurance continues to vary by employer and plan, creating a patchwork where access and cost depend on employment status, geographic location, and an employer’s coverage decisions in any given year.

Alternative pathways when insurance denies coverage

For those who do not qualify for insurance coverage or whose plans deny approval, other options exist but typically require out-of-pocket payment. Compounded semaglutide, a compounded form of the active ingredient in Wegovy made by compounding pharmacies, starts at around $149 per month through direct-pay programs. These cost less than brand-name drugs but do not come with the same FDA regulatory oversight or consistency guarantees. Novo Nordisk, which manufactures Wegovy, and Eli Lilly, which manufactures Zepbound, both operate patient savings programs and copay assistance initiatives, though enrollment and eligibility requirements vary. Some programs cap annual assistance or phase out benefits after a set time period. Understanding these alternatives is important for beneficiaries facing insurance denials or coverage gaps, as they provide a path to treatment even when the insurer says no.

Photo: Unknown · CC0 · via Wikimedia Commons